1. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. Issue 4 (April 2021) Authors: Hwang, Michael; Seiwert, Tanguy Y Journal: Lancet oncology Issue: Volume 22:Issue 4(2021) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Issue 2 (25th February 2022) Authors: Haddad, Robert I; Seiwert, Tanguy Y; Chow, Laura Q M; Gupta, Shilpa; Weiss, Jared; Gluck, Iris; Eder, Joseph P; Burtness, Barbara; Tahara, Makoto; Keam, Bhumsuk; Kang, Hyunseok; Muro, Kei; Albright, Andrew; Mogg, Robin; Ayers, Mark; Huang, Lingkang; Lunceford, Jared; Cristescu, Razvan; Cheng, Jon... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Issue 7 (July 2016) Authors: Seiwert, Tanguy Y; Burtness, Barbara; Mehra, Ranee; Weiss, Jared; Berger, Raanan; Eder, Joseph Paul; Heath, Karl; McClanahan, Terrill; Lunceford, Jared; Gause, Christine; Cheng, Jonathan D; Chow, Laura Q Journal: Lancet oncology Issue: Volume 17:Issue 7(2016:Jul.) Page Start: 956 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗